ChondroGene Limited – Trademark Portfolio
Entity Type: 03
ChondroGene Limited has 15 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO). Notable registered marks include COLONSENTRY. The portfolio includes 1 registered trademark. Filings span 5 Nice Classification classes, led by Class 5 (Pharmaceuticals) and Class 1 (Chemicals). This trademark owner is based in Toronto.
Unit 15-800 Petrolia Road
Toronto M3J 3K4 , CA
Showing of trademarks Trademarks
Trademark Classifications
ChondroGene Limited's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does ChondroGene Limited have?
ChondroGene Limited has 15 U.S. trademarks filed with the USPTO. Of these, 1 registered, 9 abandoned, 5 cancelled.
What trademark classes does ChondroGene Limited file in?
ChondroGene Limited files trademarks across 5 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are ChondroGene Limited's most well-known trademarks?
ChondroGene Limited's registered trademark portfolio includes well-known marks such as COLONSENTRY. These are among 1 currently registered trademark in the portfolio.
What is ChondroGene Limited's trademark registration success rate?
ChondroGene Limited has a 7% trademark registration rate, with 1 out of 15 resolved applications resulting in successful registration. Currently, 0 applications are pending review.